KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $2.3 billion.

  • CRISPR Therapeutics AG's Liabilities and Shareholders Equity rose 103.52% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 billion, marking a year-over-year decrease of 615.14%. This contributed to the annual value of $2.3 billion for FY2025, which is 103.52% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Liabilities and Shareholders Equity of $2.3 billion as of Q4 2025, which was up 103.52% from $2.2 billion recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Liabilities and Shareholders Equity registered a high of $2.9 billion during Q2 2021, and its lowest value of $2.0 billion during Q1 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's median Liabilities and Shareholders Equity value was $2.3 billion (recorded in 2024), while the average stood at $2.3 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Liabilities and Shareholders Equity soared by 17705.98% in 2021 and then plummeted by 1848.99% in 2022.
  • CRISPR Therapeutics AG's Liabilities and Shareholders Equity (Quarter) stood at $2.8 billion in 2021, then decreased by 18.49% to $2.2 billion in 2022, then dropped by 0.6% to $2.2 billion in 2023, then increased by 0.56% to $2.2 billion in 2024, then grew by 1.04% to $2.3 billion in 2025.
  • Its Liabilities and Shareholders Equity was $2.3 billion in Q4 2025, compared to $2.2 billion in Q3 2025 and $2.0 billion in Q2 2025.